During the last 20 years, different studies recognised 'high' MVD a poor prognostic factor for cancer patients,27–29 including women affected by OC.30 Different biomarkers have been adopted to assess MVD in OC, including Von Willebrand Factor, CD105, CD34 and CD31, being CD34 the most used MVD detector and the biomarker associated with the poorest HR for OS (HR: 1.67, CI 95%: 1.36–2.35) compared to other MVD detectors (HR: 1.32, CI 95%: 0.82–1.82).30 The gene discussed is CD34; the disease is cancer.